Article

Study: modulator in wound healing with trabeculectomy

Dorado, Puerto Rico-After positive results from a European clinical trial showed transforming growth factor-b2 (TGF-b2) mono clonal antibody was effective in delaying wound healing after first-time trabeculectomy, U.S. investigators are undertaking a multicenter clinical trial to compare the new agent with 5-fluorouracil (5-FU), reported Marshall N. Cyrlin, MD.

Related Videos
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Two-year data of bio-interventional cyclodialysis with scleral allograft with Leon W. Herndon Jr, MD
(Image credit: Ophthalmology Times) AGS 2025: Aqueous humor outflow improvement after excimer laser trabeculostomy with Clemens Strohmaier, PhD
(Image credit: Ophthalmology Times) Thomas W. Samuelson, MD, shares clinical perspectives on DSLT, SLT, and glaucoma management
Image credit: Ophthalmology Times; Dean McGee Eye Institute resident Ashley Ooms, MD, explores gray area strabismus surgery complications in AUPO poster
Image credit: Ophthalmology Times; EnVision Summit 2025: Sonia H. Yoo, MD, shares what to expect from the cataract and refractive agenda
Image credit: ©Ophthalmology Times
Wendy Lee, MD, talks about functional oculoplastics and aesthetics at EnVision Summit 2025
Related Content
Harrow to enact a 5-year strategic supply and development agreement for triamcinolone acetonide injectable suspension
March 13th 2025

Harrow to enact a 5-year strategic supply and development agreement for triamcinolone acetonide injectable suspension

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Ophthalmology sees AI-powered impact on cataract and diabetic eye disease
February 25th 2025

Ophthalmology sees AI-powered impact on cataract and diabetic eye disease

Ehsan Sadri, MD, leads an ophthalmology innovation discussion with Jeffry Weinhuff of Visionary Ventures
March 29th 2024

(EyePod) From idea to impact: Navigating ophthalmic innovation

(Image credit: AdobeStock/InsideCreativeHouse)
February 19th 2025

Alcon announces US launch of Voyager direct selective laser trabeculoplasty device

510(k) clearance issued by FDA for the VIA360 Surgical System by New World Medical
February 18th 2025

510(k) clearance issued by FDA for the VIA360 Surgical System by New World Medical

© 2025 MJH Life Sciences

All rights reserved.